BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

375 related articles for article (PubMed ID: 28331310)

  • 1. Codelivery of doxorubicin and triptolide with reduction-sensitive lipid-polymer hybrid nanoparticles for in vitro and in vivo synergistic cancer treatment.
    Wu B; Lu ST; Zhang LJ; Zhuo RX; Xu HB; Huang SW
    Int J Nanomedicine; 2017; 12():1853-1862. PubMed ID: 28331310
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Folate-containing reduction-sensitive lipid-polymer hybrid nanoparticles for targeted delivery of doxorubicin.
    Wu B; Yu P; Cui C; Wu M; Zhang Y; Liu L; Wang CX; Zhuo RX; Huang SW
    Biomater Sci; 2015 Apr; 3(4):655-64. PubMed ID: 26222425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy.
    Xu C; Song RJ; Lu P; Chen JC; Zhou YQ; Shen G; Jiang MJ; Zhang W
    Int J Nanomedicine; 2018; 13():7229-7249. PubMed ID: 30510415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fabrication Of Dual pH/redox-Responsive Lipid-Polymer Hybrid Nanoparticles For Anticancer Drug Delivery And Controlled Release.
    Men W; Zhu P; Dong S; Liu W; Zhou K; Bai Y; Liu X; Gong S; Zhang CY; Zhang S
    Int J Nanomedicine; 2019; 14():8001-8011. PubMed ID: 31632014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cellular uptake, intracellular trafficking, and antitumor efficacy of doxorubicin-loaded reduction-sensitive micelles.
    Cui C; Xue YN; Wu M; Zhang Y; Yu P; Liu L; Zhuo RX; Huang SW
    Biomaterials; 2013 May; 34(15):3858-69. PubMed ID: 23452389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy.
    Lv S; Li M; Tang Z; Song W; Sun H; Liu H; Chen X
    Acta Biomater; 2013 Dec; 9(12):9330-42. PubMed ID: 23958784
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced anti-tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles.
    Wang H; Zhao Y; Wu Y; Hu YL; Nan K; Nie G; Chen H
    Biomaterials; 2011 Nov; 32(32):8281-90. PubMed ID: 21807411
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted drug-loaded peptides induce tumor cell apoptosis and immunomodulation to increase antitumor efficacy.
    Li H; Zhang P; Yuan X; Peng S; Yang X; Li Y; Shen Z; Bai J
    Biomater Adv; 2024 Jun; 160():213852. PubMed ID: 38636118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Development and characterization of hyaluronic acid-anchored PLGA nanoparticulate carriers of doxorubicin.
    Yadav AK; Mishra P; Mishra AK; Mishra P; Jain S; Agrawal GP
    Nanomedicine; 2007 Dec; 3(4):246-57. PubMed ID: 18068091
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-Amplified pH/ROS Dual-Responsive Co-Delivery Nano-System with Chemo-Photodynamic Combination Therapy in Hepatic Carcinoma Treatment.
    Huang Y; Wu S; Li J; He C; Cheng Y; Li N; Wang Y; Wu Y; Zhang J
    Int J Nanomedicine; 2024; 19():3737-3751. PubMed ID: 38699684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Herbal compound triptolide synergistically enhanced antitumor activity of vasostatin120-180.
    Lin Y; Yang X; Lu M; Zheng W; Zhang J; Zhuang H; Hua ZC
    Anticancer Drugs; 2013 Oct; 24(9):945-57. PubMed ID: 23958791
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
    Zhang X; Wang Q; Qin L; Fu H; Fang Y; Han B; Duan Y
    Drug Deliv; 2016 Oct; 23(8):2936-2945. PubMed ID: 26739487
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergistic combination therapy of lung cancer using paclitaxel- and triptolide-coloaded lipid-polymer hybrid nanoparticles.
    Liu J; Cheng H; Han L; Qiang Z; Zhang X; Gao W; Zhao K; Song Y
    Drug Des Devel Ther; 2018; 12():3199-3209. PubMed ID: 30288024
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biotin-Conjugated Multilayer Poly [D,L-lactide-co-glycolide]-Lecithin-Polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.
    Dai Y; Xing H; Song F; Yang Y; Qiu Z; Lu X; Liu Q; Ren S; Chen X; Li N
    J Pharm Sci; 2016 Sep; 105(9):2949-2958. PubMed ID: 27209461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Luminescent/magnetic PLGA-based hybrid nanocomposites: a smart nanocarrier system for targeted codelivery and dual-modality imaging in cancer theranostics.
    Shen X; Li T; Chen Z; Geng Y; Xie X; Li S; Yang H; Wu C; Liu Y
    Int J Nanomedicine; 2017; 12():4299-4322. PubMed ID: 28652734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Two-component reduction-sensitive lipid-polymer hybrid nanoparticles for triggered drug release and enhanced in vitro and in vivo anti-tumor efficacy.
    Zhang LJ; Wu B; Zhou W; Wang CX; Wang Q; Yu H; Zhuo RX; Liu ZL; Huang SW
    Biomater Sci; 2016 Dec; 5(1):98-110. PubMed ID: 27841378
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid nanoparticles loading triptolide for transdermal delivery: mechanisms of penetration enhancement and transport properties.
    Gu Y; Yang M; Tang X; Wang T; Yang D; Zhai G; Liu J
    J Nanobiotechnology; 2018 Sep; 16(1):68. PubMed ID: 30217198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy.
    He Y; Su Z; Xue L; Xu H; Zhang C
    J Control Release; 2016 May; 229():80-92. PubMed ID: 26945977
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic breast tumor cell killing achieved by intracellular co-delivery of doxorubicin and disulfiram via core-shell-corona nanoparticles.
    Tao X; Gou J; Zhang Q; Tan X; Ren T; Yao Q; Tian B; Kou L; Zhang L; Tang X
    Biomater Sci; 2018 Jun; 6(7):1869-1881. PubMed ID: 29808221
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lipid-polymer hybrid nanoparticles for controlled delivery of hydrophilic and lipophilic doxorubicin for breast cancer therapy.
    Tahir N; Madni A; Correia A; Rehman M; Balasubramanian V; Khan MM; Santos HA
    Int J Nanomedicine; 2019; 14():4961-4974. PubMed ID: 31308666
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.